Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ENTA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Zelicapavir | RSV | Phase 2/3 · NCT07908381 | Recruiting |
| EDP-938 | RSV Infection | Phase 2 · NCT05568706 | Completed |
| EDP-323 Dose Regimen 1 | RSV Infection | Phase 2 · NCT06170242 | Completed |
| EDP-323 Dose Regimen 2 | RSV Infection | Phase 2 · NCT06170242 | Completed |
| EDP-420 / Duration of Treatment - 3 days | Community Acquired Pneumonia | Phase 2 · NCT00270517 | Unknown |
| EDP-305 Dose 2 | Non-Alcoholic Steatohepatitis | Phase 2 · NCT03421431 | Completed |
| EDP-305 Dose 1 | Non-Alcoholic Steatohepatitis | Phase 2 · NCT03421431 | Completed |
| EDP-305 | Primary Biliary Cholangitis | Phase 2 · NCT03394924 | Completed |
| EDP-938 Dose 1 | RSV Infection | Phase 2 · NCT03691623 | Completed |
| EDP-235 | COVID-19 | Phase 2 · NCT05616728 | Completed |
| EDP-938 Dose 2 | RSV Infection | Phase 2 · NCT03691623 | Completed |
| EDP-938 Dose 3 | RSV Infection | Phase 2 · NCT03691623 | Completed |
| Telithromycin | Community Acquired Pneumonia | Phase 2 · NCT00270517 | Unknown |
| EDP-938 Dose 4 | RSV Infection | Phase 2 · NCT03691623 | Completed |
| intraconazole | NASH - Nonalcoholic Steatohepatitis | Phase 1 · NCT03213145 | Completed |
| EDP239 | Hepatitis C | Phase 1 · NCT01856426 | Completed |
Also used in these trials (approved or third-party drugs, not ENTA's own candidates): Itraconazole, Prednisone, Fluconazole, Midazolam Hydrochloride, Rifampin, Tacrolimus Extended-Release, Caffeine, Dabigatran Etexilate, Cyclosporine, Carbamazepine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ENTA holds $211.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 74.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 24 · Moderate
Based on our operating plan, we believe that our existing cash, cash equivalents and short-term and long-term marketable securities as of June 30, 2026, as well as the cash flows from our retained portion of future HCV royalties, will enable us to fund our operating expenses and capital expenditure requirements into…10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENTA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Dapice Joshua J. | 5%+ holder (13G) | 2,816,862 | 9.67% | 2025-12-31 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 1,733,320 | 5.95% | 2026-09-30 |
| Jay R. Luly, Ph.D. | 5%+ holder (13D) | 1,703,616 | 5.85% | 2025-02-12 |
| BlackRock Portfolio Management LLC | Institution (13G, 5%+) | 1,560,091 | 5.36% | 2026-09-30 |
| Jay R. Luly President and CEO, Director · +310,000 options |
Insider | 871,871 | 2.99% | 2026-02-12 |
| Yat Sun Or Chief Scientific Officer · +110,000 options |
Insider | 374,854 | 1.29% | 2026-02-12 |
| Brendan Luu Chief Business Officer · +90,000 options |
Insider | 41,634 | 0.14% | 2026-02-12 |
| Tara Lynn Kieffer Chief Product Strategy Officer · +100,000 options |
Insider | 33,925 | 0.12% | 2026-02-12 |
| Scott T. Rottinghaus Chief Medical Officer · +110,000 options |
Insider | 23,787 | 0.08% | 2026-08-08 |
| Harry R. III Trout Vice President, Finance (Principal Finan · +12,925 options |
Insider | 16,348 | 0.06% | 2025-12-05 |
| Kathleen S. Capps Executive Director of Accounting, Contro · +6,325 options |
Insider | 8,377 | 0.03% | 2025-12-05 |
| Matthew Paul Kowalsky Chief Legal Officer · +90,000 options |
Insider | 3,591 | 0.01% | 2026-02-12 |
Share count 29,125,402 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENTA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →